Clinical trials: Major Depressive Disorder \(MDD
Depression, End Stage Renal Disease
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
Patients whose kidneys fail generally require dialysis treatments to sustain life. The ability of patients to make major adjustments in their lives for dialysis is hampered by depression that affects almost one-quarter of such…
- Trial name
- ASCEND (NCT02358343)
- Testing
- Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
- Where
- 3 sites in United States
- Volunteers
- 184 people
- Sponsor
- University of Washington
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Major Depressive Disorder
Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients
This study is an open-label, randomized, multi-center study conducted in a typical psychiatric outpatient practice in China. This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus…
- Trial name
- NCT00474708
- Testing
- Effexor, SSRI
- Where
- 26 sites in China
- Volunteers
- 1,151 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Combining Medications to Enhance Depression Outcomes
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
- Trial name
- CO-MED (NCT00590863)
- Testing
- Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
- Where
- 15 sites in United States
- Volunteers
- 665 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00798707
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Where
- 78 sites in United States, Japan
- Volunteers
- 709 people
- Sponsor
- Pfizer
Suicidal Ideation, Suicide Attempt
Youth Suicide Prevention: CAMS-BI vs. Safety Planning in a Randomized Trial
This study outlines a randomized controlled trial evaluating two brief suicide-specific interventions for adolescents aged 12-17 who are hospitalized for suicidal ideation or attempts.
- Conditions
- Suicidal Ideation, Suicide Attempt, Safety Plan, Depression / Major Depressive Disorder
- Trial name
- NCT07628192
- Testing
- CAMS Brief Intervention, Stanley-Brown Safety Planning Intervention
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- The Cleveland Clinic
Depression
Imaging Biomarkers for TMS Treatment of Depression
The purpose of this research is to learn more about how rTMS works to reduce the symptoms of depression. This information can be used to improve the effectiveness of the treatment.
- Trial name
- NCT01900314
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Major Depressive Disorder
Does Dual Therapy Hasten Antidepressant Response?
This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates…
- Trial name
- NCT00519428
- Testing
- escitalopram, bupropion extra long (XL), escitalopram + bupropion
- Where
- 2 sites in United States, Canada
- Volunteers
- 245 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
- Trial name
- NCT01500200
- Testing
- ALKS 5461
- Where
- 27 sites in United States
- Volunteers
- 142 people
- Sponsor
- Alkermes, Inc.
Major Depression
Efficacy Study of Botox for Depression
The objective of this proposed study is to obtain data on the efficacy of Botox in reducing symptoms of MDD in male and female patients between the ages of 18 and 65 years old.
- Trial name
- NCT01556971
- Testing
- Botox, Saline Solution
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Capital Clinical Research Associates, LLC
Major Depressive Disorder
Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation
This study characterized the impact of respiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry, vagal tone and depressed mood in patients with major depressive disorder…
- Trial name
- tVNS-MDD (NCT04467164)
- Testing
- exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS), Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Duloxetine Versus Paroxetine for Major Depression
To determine if duloxetine works just as well as paroxetine in the treatment of major depressive disorder.
- Trial name
- NCT00489775
- Testing
- Duloxetine, Paroxetine
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression
The purpose of this research study is to learn whether specific types of brain imaging and psychological testing can predict how much benefit patients with depression will receive from a well-studied psychotherapy for depression…
- Trial name
- NCT01922219
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Major Depression
Cognitive Behavioral Treatments for Depression in Chronic Illness
Duke University Medical Center in collaboration with Glendale Adventist Medical Center propose a randomized clinical trial of conventional cognitive behavior therapy (CCBT) vs.
- Trial name
- NCT01208428
- Testing
- Conventional cognitive behavioral therapy, Religious cognitive behavioral therapy
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Duke University
Depressive Disorder
Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy
Whether high-dose omega-3 fatty acids supplement would be an effective treatment in patients with major depressive disorder during pregnancy and breast-feeding.
- Trial name
- NCT00618865
- Testing
- Omega-3 fatty acids
- Volunteers
- 36 people
- Sponsor
- National Science and Technology Council, Taiwan
Depressive Disorder, Major
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for participants with major depressive disorder (MDD), who were identified as partial responders to an adequate course…
- Trial name
- NCT00840034
- Testing
- LY2216684
- Where
- 24 sites in United States
- Volunteers
- 227 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Pharmacogenomic Testing in Major Depressive Disorder
This is a two-arm double-blind prospective randomized controlled trial (RCT) to evaluate clinical impact of pharmacogenomic testing on the treatment of major depressive disorder.
- Trial name
- NCT03228953
- Testing
- Pharmacogenomic testing
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Columbia University
Major Depressive Disorder, Recurrent, in Remission
Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to…
- Trial name
- NCT05423275
- Testing
- Negative ion therapy, Light therapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Major Depressive Disorder (MDD
A Study of ONO-1110 in Patients With Major Depressive Disorder
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Major Depressive Disorder
- Trial name
- NCT06792136
- Testing
- ONO-1110
- Where
- 29 sites in Japan
- Volunteers
- 103 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Depressive Disorder, Major
Acupuncture and Escitalopram for Treating Major Depression Clinical Study
We will be able to investigate in a sample of patients free of antidepressants whether acupuncture is more effective than placebo.
- Trial name
- AE-TMDCS (NCT05901571)
- Testing
- acupuncture, escitalopram
- Where
- 3 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai 7th People's Hospital